Illegal Possession of Drugs: Polish Man Faces 10-Year Sentence

Regulations by 2FIRSTS.ai
Nov.28.2023
Illegal Possession of Drugs: Polish Man Faces 10-Year Sentence
A housing in Lublin, Poland drew police attention due to excessive noise, leading to the discovery of drugs and illegal e-cigarettes.

In recent days, a housing property in Lublin, Poland, attracted police attention due to excessive nighttime noise. During the investigation, the police discovered a quantity of drugs and illegal e-cigarettes, leading to the detention of all individuals present at the scene.

 

After conducting a further search of the 24-year-old man's room, the authorities have discovered 850 grams of ephedrine and 200 e-cigarettes without the required Polish tax stamps.

 

Currently, a 24-year-old man has been charged with the illegal possession of a large quantity of drugs. According to the court's decision, he will be temporarily detained for three months and could potentially face a maximum sentence of 10 years imprisonment.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

South Korea’s Parliament Reconsiders Bill to Regulate Synthetic Nicotine as Tobacco
South Korea’s Parliament Reconsiders Bill to Regulate Synthetic Nicotine as Tobacco
South Korea’s National Assembly is once again reviewing a bill to classify synthetic nicotine as a tobacco product under the Tobacco Business Act. The proposal aims to close regulatory loopholes that allow untaxed, unregulated nicotine liquids — often used by minors — to circulate freely. Lawmakers expect the bill to pass during the current session amid growing public and civic pressure.
Nov.26 by 2FIRSTS.ai
2Firsts Monitor | FOGER website flags customs & tariff delays; some products out of stock
2Firsts Monitor | FOGER website flags customs & tariff delays; some products out of stock
2Firsts observed on FOGER’s online retail site “FOGER VAPES” that the platform indicates restocking delays due to customs and tariff factors. Several items show limited availability or “sold out” status, with a restock alert feature offered. A previous article on the site also referenced potential tariff changes that may affect pricing.
Nov.05
China’s E-Cigarette Exports Rise to USD 1.098 Billion in October 2025, Up 23.7% Year-on-Year as U.S. Demand Surges
China’s E-Cigarette Exports Rise to USD 1.098 Billion in October 2025, Up 23.7% Year-on-Year as U.S. Demand Surges
China’s e-cigarette exports reached USD 1.098 billion in October 2025, rising 24.8% month-on-month and 23.7% year-on-year, according to the latest data released by the General Administration of Customs of China. Export concentration increased to 83.11%, with the U.S. market contributing the largest share of monthly growth.
Nov.21 by 2FIRSTS.ai
Nicotine Pouch Brand VELO and McLaren Unveil Special Livery for the Abu Dhabi Grand Prix
Nicotine Pouch Brand VELO and McLaren Unveil Special Livery for the Abu Dhabi Grand Prix
According to PRNewswire, VELO and the McLaren Formula 1 Team have unveiled a special livery for the Abu Dhabi Grand Prix, co-created by nine superfans from around the world. The design forms the highlight of the “Live Your Fandom” campaign, reflecting memorable fan stories and celebrating the global McLaren community.
Dec.04 by 2FIRSTS.ai
ZYN Nicotine Pouches Seek MRTP Authorization; FDA Sets January Meeting
ZYN Nicotine Pouches Seek MRTP Authorization; FDA Sets January Meeting
The U.S. FDA has scheduled a Tobacco Products Scientific Advisory Committee (TPSAC) meeting for January 22, 2026, to review Swedish Match USA’s Modified Risk Tobacco Product (MRTP) applications for 20 ZYN nicotine pouch products. Although the products gained PMTA authorization in early 2025, MRTP approval is required for marketing them with reduced-risk claims.
Nov.24 by 2FIRSTS.ai
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai